TwinBeech Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
Other funds holding MLTX
TwinBeech Capital's MLTX Position: Q3 2026 in Review
TwinBeech Capital opened a new position in MoonLake Immunotherapeutics (MLTX) in Q3 2026: 14,516 shares worth $170K. The stake represents 0.04% of the portfolio and ranks #362 among its holdings. This is a return to the name: TwinBeech Capital previously reported a position in MLTX as recently as Q3 2025.
TwinBeech Capital first reported a position in MLTX in Q2 2024 and has held it in 3 quarters since. The position peaked at $2.57M in Q2 2024. 167 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.
- TwinBeech Capital held 14,516 shares of MoonLake Immunotherapeutics worth $170K as of Q3 2026.
- MoonLake Immunotherapeutics was a new TwinBeech Capital position in Q3 2026.
- MoonLake Immunotherapeutics made up 0.04% of TwinBeech Capital's portfolio in Q3 2026, its #362 holding.
- TwinBeech Capital first reported a position in MoonLake Immunotherapeutics in Q2 2024 and has held it in 3 quarters since.
- TwinBeech Capital's MoonLake Immunotherapeutics position peaked at $2.57M in Q2 2024.
- 167 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.
Based on TwinBeech Capital's 13F filing for Q3 2026, filed 16 Nov 2026.